Barrington analyst Michael Petusky lowered the firm’s price target on Dentsply Sirona (XRAY) to $14 from $18 and keeps an Outperform rating on the shares. While stating that Dentsply Sirona has “turned into the ultimate ‘prove it” story,” the firm believes the current valuation reflects “maximum skepticism” and argues that the risk/reward continues to favor investors with patience.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- Dentsply Sirona price target lowered to $12 from $14 at Morgan Stanley
- Dentsply Sirona price target lowered to $13 from $16 at Mizuho
- Dentsply Sirona price target lowered to $12 from $14 at JPMorgan
- Dentsply Sirona price target lowered to $14 from $18 at Baird
- Dentsply Sirona price target lowered to $13 from $16 at Piper Sandler